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Abstract
Background: Bone morphogenetic protein-6 (BMP-6) is critically involved in many developmental processes. Recent
studies indicate that BMP-6 is closely related to tumor differentiation and metastasis.
Methods: Quantitative RT-PCR was used to determine the expression of BMP-6, E-cadherin, and δEF1 at the mRNA
level in MCF-7 and MDA-MB-231 breast cancer cells, as well as in 16 breast cancer specimens. Immunoblot analysis was
used to measure the expression of δEF1 at the protein level in δEF1-overexpressing and δEF1-interfered MDA-MB-231
cells. Luciferase assay was used to determine the rhBMP-6 or δEF1 driven transcriptional activity of the E-cadherin
promoter in MDA-MB-231 cells. Quantitative CHIP assay was used to detect the direct association of δEF1 with the E-
cadherin proximal promoter in MDA-MB-231 cells.
Results: MCF-7 breast cancer cells, an ER+ cell line that expressed high levels of BMP-6 and E-cadherin exhibited very
low levels of δEF1 transcript. In contrast, MDA-MB-231 cells, an ER- cell line had significantly reduced BMP-6 and E-
cadherin mRNA levels, suggesting an inverse correlation between BMP-6/E-cadherin and δEF1. To determine if the same
relationship exists in human tumors, we examined tissue samples of breast cancer from human subjects. In 16 breast
cancer specimens, the inverse correlation between BMP-6/E-cadherin and δEF1 was observed in both ER+ cases (4 of 8
cases) and ER- cases (7 of 8 cases). Further, we found that BMP-6 inhibited δEF1 transcription, resulting in an up-
regulation of E-cadherin mRNA expression. This is consistent with our analysis of the E-cadherin promoter
demonstrating that BMP-6 was a potent transcriptional activator. Interestingly, ectopic expression of δEF1 was able to
block BMP-6-induced transactivation of E-cadherin, whereas RNA interference-mediated down-regulation of
endogenous δEF1 in breast cancer cells abolished E-cadherin transactivation by BMP-6. In addition to down-regulating
the expression of δEF1, BMP-6 also physically dislodged δEF1 from E-cadherin promoter to allow the activation of E-
cadherin transcription.
Conclusion: We conclude that repression of δEF1 plays a key role in mediating BMP-6-induced transcriptional activation
of E-cadherin in breast cancer cells. Consistent with the fact that higher level of δEF1 expression is associated with more
invasive phenotype of breast cancer cells, our collective data suggests that δEF1 is likely the switch through which BMP-
6 restores E-cadherin-mediated cell-to-cell adhesion and prevents breast cancer metastasis.
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Background
Breast cancer is the most common neoplasm in women.
The unique histological features of breast cancer are
prominent proliferation of epithelial cells and the forma-
tion of ectopic mesenchymal tissue, including cartilage
and bone, especially in complex adenomas and benign
mixed tumors [1,2]. The association between loss or
down-regulation of E-cadherin, an epithelial cell-cell
adhesion protein, and progression of breast cancer has
been extensively documented [3,4]. Tumor cells acquire
invasive properties when E-cadherin-mediated adhesion
is inhibited [5,6]. In line with these findings, ectopic
expression of E-cadherin in a transgenic mouse model
prevented tumor cell invasion and metastasis [7]. Several
epigenetic mechanisms are implicated in E-cadherin loss
during breast cancer, including hypermethylation of the
E-cadherin promoter region at CpG islands [8] and tran-
srepression by specific transcriptional factors. Several zinc
finger transcription factors, such as Twist [9,10], Snail1
[11-14], Snail2 [15,16], SIP1 [17], and E12/E47 [16], have
been found to bind to the E-box elements in the proximal
E-cadherin promoter and repress its transcription. Moreo-
ver, a few factors, including ErbB2 [18], TGF-β [19], and
estrogen [20], were reported to regulate E-cadherin expres-
sion.
Bone morphogenetic protein-6 (BMP-6), a member of
TGF-β superfamily, has been characterized as a multifunc-
tional molecule with a distinct ability to induce ectopic
cartilage and bone formation [1,21]. In vitro, BMP-6
inhibits cell division, promotes cell differentiation,
induces ectopic bone formation, and regulates epithelial-
mesenchymal interaction [21-24]. Furthermore, a
number of recent studies have shown that BMP-6 expres-
sion is associated with progression of tumorigenesis.
BMP-6 is detected in several human neoplastic epithelial
cells including breast, prostate, salivary, rectal, and thy-
roid carcinomas, and is speculated to be closely associated
with tumor metastasis [21,25-29].
δEF1, a member of the zinc finger-homeodomain family
of transcription factors [30,31], was originally identified
as a binding protein of the lens-specific δ1-crystalline
enhancer in chicken [32]. Studies revealed that δEF1 is a
widely expressed transcriptional repressor, working
through its zinc finger clusters binding to consensus E-
box-like sequences, 5'-CA(G/C)(G/C)TG-3' [33-35]. Sev-
eral recently reported properties mark δEF1 as a potential
regulatory factor in various cellular processes during
tumor progression. In lung and breast tumor cells, δEF1
has been implicated in epithelial to mesenchymal transi-
tion (EMT) [36-38], a process associated with tumor
metastasis [39]. Moreover, δEF1 can itself be regulated by
hormones in target tissues [40-42]. In one example, δEF1
is up-regulated by estrogen in the chick oviduct and is
responsible for estrogen-mediated regulation of the oval-
bumin gene [40,41,43]. In human T47D breast carcinoma
cells, δEF1 is up-regulated by progesterone via both iso-
forms of the progesterone receptor (PR) [42].
In this communication, we report that BMP-6 up-regu-
lates the expression of E-cadherin at the mRNA level in
breast cancer cells, determined by quantitative RT-PCR
and luciferase assay. We demonstrate that this effect is a
direct result of BMP-6-indcued down-regulation of δEF1.
The inverse relationship between BMP-6/E-cadherin and
δEF1 were validated in 16 breast cancer specimens using
quantitative RT-PCR. This finding contributes signifi-
cantly to our understanding of the potential role of BMP-
6 and δEF1 in breast tumorigenesis and metastasis.
Methods
Tumor Samples
Fresh breast cancer tissues of invasive ductal carcinoma
(stage II) were obtained from the Tissue Banking Facility
Jointly Supported by TMUCIH (Tianjin Medical Univer-
sity Cancer Institute and Hospital) & NFCR (National
Foundation for Cancer Research). The pathological stage
and nodal status were obtained from the primary pathol-
ogy reports. The patients (8 ER positive and 8 ER negative)
had a mean age of 52.8 ± 12.1 years and were recruited in
the same department. This study was approved by the
institutional ethics committee.
Cell Culture
MCF-7 and MDA-MB-231 cells were maintained in
DMEM-high glucose medium (GIBCO BRL, Grand Island,
NY, USA) supplemented with 10% FBS (Hyclone, Logan,
Utah, USA), penicillin, and streptomycin according to the
recommendations of the American Type Culture Collec-
tion (ATCC). MDA-MB-231 cells were plated at a density
of 2 × 104 cells/well in 24-well plates and 8 × 104 in 6-well
plates for use in quantitative RT-PCR and luciferase assays,
respectively. The cells were cultured in the presence or
absence of 200 ng/ml rhBMP-6 (R&D Systems, Minneap-
olis, MN, USA) in DMEM supplemented with 5% FBS.
Plasmid Constructs
cDNA fragment encoding the full-length δEF1 sequence
was prepared by PCR using the forward primer, 5'-CGCG-
GATCCAGGATCATGGCGGATGGC-3', and reverse
primer, 5'-GAACCTCGAGCGAGCTTCATTTGTCT-
TCTCTTC-3'. The PCR products were digested with
BamHI/XhoI, and cloned into pcDNA6B (Life Technolo-
gies, Grand Island, NY, USA). The E-cadherin promoter
sequence (-308/+21) was obtained by PCR from human
blood genomic DNA and cloned into the pGL4.10 vector
(Promega, Madison, WI, USA) as described by Comijn et
al. [17]. Mutagenesis of the δEF1 sites in the human E-cad-
herin promoter was performed using the QuickChangeBMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA) with the forward primer E2 box 1: 5'-gctgtggccggCA-
GATGaaccctcag-3' and reverse primer E2 box 1: 5'-ctgag-
ggttCATCT Gccggccacagc-3'; forward primer E2 box 3: 5'-
gctccgggctCATCTGgctgcag c-3' and reverse primer E2 box
3: 5'-gctgcagcCAGATGagccccggagc-3', as described by
Comijn et al. [17].
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from MCF-7 and MDA-MB-231
cells treated with or without 200 ng/ml rhBMP-6 for vari-
ous times or from 16 breast cancer specimens using the
TRIzol Reagent (Life Technologies, Grand Island, NY,
USA). Total RNA (0.5 µg) from each sample was used for
first strand cDNA synthesis (M-MLV Reverse Tran-
scriptase, Promega, Madison, WI, USA). Specific products
of human δEF1, human E-cadherin, and human BMP-6
were amplified by quantitative PCR using the following
primers:  δEF1, 5'-GGCCCCAGGTGTAAGCGC-3' (for-
ward), and 5'-CAGGCCCCAGGATTTCTTG C-3' (reverse);
E-cadherin, 5'-TGCTGCAGGTCTCCTCTTGG-3' (for-
ward), and 5'-AGT CCCAGGCGTAGACCAAG-3'
(reverse); BMP-6, 5'-CAACAGAGTCGTAATCA-3' (for-
ward), and 5'-TTAGTGGCATCCACAAGCTCT-3' (reverse).
GAPDH was used as an internal control. Verification of
the expression levels of genes was performed by quantita-
tive RT-PCR using EvaGreen (Botium, Hayward, CA,
USA). The expression level was expressed as the threshold
cycle (CT) values of the target and reference gene-GAPDH,
which is constitutively expressed and not regulated by
treatment with rhBMP-6. Comparison and calculation of
CT  values was used to determine the relative mRNA
expression expressed as the fold change of target genes rel-
ative to the reference gene.
Antibodies
The following antibodies (Abs) were used: mouse mono-
clonal Ab against c-Myc (sc-40, Santa Cruz Biotechnology,
CA, USA); goat polyclonal Ab against the N-terminal
epitope of δEF1 (ZEB-E20, Santa Cruz Biotechnology, CA,
USA); a mouse monoclonal Ab against E-cadherin
(610181, BD Transduction Laboratories, KY, USA); and a
mouse monoclonal Ab against FLAG-M2 (F-3165, Sigma,
MO, USA).
Western Immunoblot Analysis
MDA-MB-231 cells were solubilized in lysis buffer (50
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton ×-100,
0.5% sodium deoxycholate) supplemented with apro-
tinin (10 µg/ml), leupeptin (10 µg/ml), and PMSF (1
mM). The lysates were cleared by centrifugation and the
protein concentrations were determined using the BCA
Protein Assay Kit (Pierce, Rockford, IL, USA). Proteins
were separated by SDS-PAGE and transferred onto nitro-
cellulose membranes (Amersham Biosciences, Piscata-
way, NJ, USA). Western blotting was performed using
standard techniques and immunoreactive bands were
detected by chemiluminescence (ECL, Amersham Bio-
sciences, Piscataway, NJ, USA).
Luciferase Assay
MDA-MB-231 cells were co-transfected with wild-type or
mutant human E-cadherin promoter constructs and dif-
ferent amounts of δEF1 expression plasmids (1.5, 3.0, and
6.0 µg/well) in 6-well plates using Lipofectamine 2000
(Invitrogen, Austin, TX, USA). Cells were treated with
rhBMP-6 (200 ng/ml) for 24 h after transfection. Lysates
were prepared 24 h after treatment. The luciferase activity
was then measured using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI, USA) according to
the manufacturer's instructions. Luciferase activity was
normalized using the Renilla luciferase activity.
Preparation of small interfering RNAs and Transfection
The target sequence of the siRNA is 5'-TGATCAGCCT-
CAATCTGCA-3' for human δEF1 as previously reported
[36]. The sense and antisense oligonucleotides with the
internal loop were synthesized (TaKaRa, Shiga, Japan).
These were annealed and ligated into the BamHI and Hin-
dIII sites of pSilencer 4.1-CMVneo (Ambion, Carlsbad,
CA, USA) to construct the δEF1-specific siRNA expression
plasmid according to the manufacturer's instructions. pSi-
lencer 4.1-CMVneo expressing a scrambled siRNA
(Ambion, Carlsbad, CA, USA) was used as a control. Tran-
sient transfection with siRNAs was performed with Lipo-
fectamine 2000 (Invitrogen, Austin, TX, USA) in MDA-
MB-231 cells. G418-resistent clones were isolated over a
period of 3–4 weeks. Down-regulation of δEF1 was con-
firmed by western immunoblot analysis.
Quantitative CHIP Assays
MDA-MB-231 cells were grown for 24 h up to 80% con-
fluence in the presence or absence of 200 ng/ml rhBMP-6.
Cells were cross-linked with 1% formaldehyde and proc-
essed using the Chromatin Immunoprecipitation (ChIP)
Assay Kit (Updates, Lake Placid, NY, USA). The following
antibodies (10 µg) were used: anti-ZEB, a polyclonal anti-
body raised against N-terminal epitopes of δEF1, or unre-
lated anti-FLAG control antibody (F-3165, Sigma, MO,
USA) with 100 µg of chromatin per CHIP. Purified immu-
noprecipitated DNA was used for quantitative PCR reac-
tions. The primers used for this analysis were as follows:
5'-AGGCTAGAGGGTCACCGCGTC-3' (forward), and 5'-
GCTTTGCAGTTCCGACGCCAC-3' (reverse). Copy num-
bers for the DNA fragments (-175 to +21) of E-cadherin
promoter in each anti-ZEB sample with or without BMP-
6 induction were determined and compared to copy num-
bers of the DNA fragment without IP (input DNA). Anti-
FLAG antibody was used as a control for IP reactions. The
percentage of the input was then calculated. The finalBMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
Page 4 of 13
(page number not for citation purposes)
value was the percentage input obtained with specific
antibody minus the percentage input obtained with anti-
FLAG control antibody. The dissociation curve was deter-
mined for each quantitative PCR to ensure that a single
band was produced. Each data point represents three
independent samples.
Results
Expression levels of BMP-6 and E-cadherin are inversely 
related to that of δEF1 in breast cancer cell lines and in 
clinical breast cancer specimens
MCF-7 and MDA-MB-231 breast cancer cells feature dif-
ferent capacities for invasiveness and metastasis in vivo
and, as such, have been intensively used as tumor models
during past few years [44]. Our preliminary studies indi-
cated that expressions of BMP-6 and δEF1 were inversely
related in MCF-7 and MDA-MB-231 cells. MDA-MB-231
Expression of BMP-6, E-cadherin, and δEF1 in MCF-7 and MDA-MB-231 breast cancer cells is inversely correlated Figure 1
Expression of BMP-6, E-cadherin, and δEF1 in MCF-7 and MDA-MB-231 breast cancer cells is inversely corre-
lated. (a) Transcript levels of BMP-6, E-cadherin, and δEF1 in MCF-7 and MDA-MB-231 breast cancer cells were detected by 
RT-PCR analysis. GAPDH was used as an internal control. (b) The agarose gel electrophoresis data was quantified by UV band 
scanning. Data represent three independent experiments.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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cells, which express high level of δEF1 mRNA, exhibited
very low level of BMP-6 (Figure 1). In contrast, MCF-7
cells had markedly reduced δEF1 mRNA levels (Figure 1).
Moreover, δEF1 has recently been identified as a direct
transcriptional repressor of E-cadherin in these cancer
cells [36]. We therefore performed RT-PCR to examine the
expression of E-cadherin in MCF-7 and MDA-MB-231
cells. Consistent with the previously reported results
[13,36], E-cadherin mRNA expression was high in MCF-7
cells, but undetectable in MDA-MB-231 cells (Figure 1).
After establishing the relationship between BMP-6, E-cad-
herin, and δEF1 in cancer cell lines, we moved on to vali-
date this finding in breast cancer tissue samples. We
collected 16 tumor specimens (T1–T8 were ER positive
and T9–16 were ER negative) and analyzed their relative
mRNA levels using quantitative RT-PCR. As shown in Fig-
ure 2b, an inverse correlation between BMP-6/E-cadherin
and δEF1 is clearly evident in ER- cancer specimens (7 out
of 8: T9, T10, T11, T13, T14, T15, T16). Only in T12 was
the low δEF1 level not accompanied by an increased level
of E-cadherin/BMP-6. In ER+ cancer specimens, a clear
inverse correlation was evident in T1, T3, T7, and T8 (Fig-
ure 2a). However, in the other ER+ tumor samples such an
inverse correlation was not as evident. In addition, our
results revealed that expression of BMP-6 in ER+ breast
tumor specimens was comparatively higher than in ER-
cases. However, for expression of δEF1 in ER+ and ER-
breast tumor specimens, this relationship was reversed;
here ER+ tumors had lower δEF1 mRNA levels than ER-.
Together, these data suggest a strong inverse relationship
between the expressions of BMP-6/E-cadherin and δEF1,
which could contribute to the invasiveness and metastatic
capacity of breast cancer cells.
BMP-6 down-regulated δEF1 and concurrently promoted 
E-cadherin transcription in breast cancer cells
To assess whether a loss of E-cadherin expression in MDA-
MB-231 cells is related to the presence of δEF1 suppres-
sion as well as a deficiency of BMP-6, the cells were cul-
tured in the presence or absence of rhBMP-6. Total RNA
was extracted at 0, 3, 12, 24, 48, 72, and 96 h following
BMP-6 treatment. Quantitative RT-PCR analysis demon-
strated that BMP-6 treatment for 72 h resulted in an up to
60% decrease in the expression of δEF1 mRNA, compared
to the basal level (Figure 3a). Meanwhile, BMP-6 treat-
ment for 96 h increased the expression of E-cadherin more
than 8-fold over the level at baseline (Figure 3b). In the
sequence of time, the BMP-6-induced down-regulation of
δEF1 transcription occurred at as early as 3 h; whereas up-
regulation of E-cadherin was observed only after 12 h of
BMP-6 induction (Figure 3a and 3b), suggesting that
BMP-6-induced down-regulation of δEF1 may well be a
pre-requisite to allow the expression of E-cadherin.
To verify these findings, western blot was performed to
determine BMP-6-modulated expression of δEF1 and E-
cadheirn at the protein level. This time, MDA-MB-231
cells were cultured in the presence or absence of 200 ng/
ml rhBMP-6 and total protein lysates were collected at 24
and 48 h following treatment. Western blot analysis
revealed that BMP-6 treatment for 48 h significantly
reduced the level of δEF1 protein (Figure 3c) with the
expression of E-cadherin being up-regulated concurrently
(Figure 3d).
Relative expression levels of BMP-6, E-cadherin, and δEF1 in 16 breast cancer specimens Figure 2
Relative expression levels of BMP-6, E-cadherin, and δEF1 in 16 breast cancer specimens. Transcript levels of the 
three genes were determined in tumor samples from 16 breast cancer specimens by quantitative RT-PCR. GAPDH was used 
to normalize the individual expression levels.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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BMP-6-induced transcription of endogenous E-cadherin 
was suppressed by δEF1 in MDA-MB-231 cells
With the knowledge that BMP-6 represses δEF1 transcrip-
tion and causes up-regulation of E-cadherin in MDA-MB-
231 cells, we moved on to examine whether BMP-6 is a
bona fide stimulator of E-cadherin expression in MDA-MB-
231 cells using reporter gene assays. The study showed
that BMP-6 significantly stimulated E-cadherin promoter
activity of the wild-type -308/+21 reporter gene, com-
pared to the empty-vector transfected control cells (Figure
4b, lane 1 verse 2). Furthermore, we examined whether
δEF1 overexpression could repress the BMP-6-induced
transcriptional activation of E-cadherin. MDA-MB-231
cells were co-transfected with E-cadherin promoter
reporter and δEF1 expression plasmid in the presence of
rhBMP-6. Overexpression of δEF1 was confirmed by west-
ern blot (Figure 4a). As anticipated, δEF1 expression sig-
nificantly inhibited the promoter activity of E-cadherin
BMP-6 down-regulates δEF1 and concurrently up-regulates E-cadherin transcription in MDA-MB-231 breast cancer cells Figure 3
BMP-6 down-regulates δEF1 and concurrently up-regulates E-cadherin transcription in MDA-MB-231 breast 
cancer cells. (a) BMP-6-induced (200 ng/ml) down-regulation of δEF1 mRNA in MDA-MB-231 cells was verified by quantita-
tive RT-PCR. GAPDH was used to normalize the δEF1 level. Data represent three independent experiments. (b) BMP-6-
induced (200 ng/ml) up-regulation of E-cadherin mRNA in MDA-MB-231 cells was verified by quantitative RT-PCR. GAPDH 
was used to normalize the E-cadherin level. Data represent three independent experiments. (c) Western blot with anti-ZEB 
antibody showing δEF1 expression in MDA-MB-231 cells after culture for 24 or 48 h with BMP-6 (200 ng/ml). Actin expression 
was used as an internal control. (d) Western blot with anti-E-cadherin antibody showing E-cadherin expression in MDA-MB-
231 cells after culture for 24 or 48 h with BMP-6 (200 ng/ml). Actin expression was used as an internal control.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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being activated by rhBMP-6 (Figure 4b, lane 2 verse 4),
confirming a role for δEF1 in suppressing transcriptional
activation of E-cadherin by inducers such as BMP-6.
To further address the specificity of δEF1 in regulation of
E-cadherin promoter, we mutated two δEF1-binding sites
identified in the human E-cadherin promoter (-308/+21),
individually or in combination (Figure 5). The mutant E-
cadherin promoter constructs were then co-transfected
with δEF1 expression plasmid in the presence of rhBMP-
6. A measurement of luciferase activity indicated that δEF1
expression inhibited BMP-6-induced reporter activity of
the E-cadherin promoter harboring mutations in either E-
box 1 or E-box 3 (Figure 4b, lane 6 verse 8, lane 10 verse
12), an effect similar to that of δEF1 on the wild-type E-
cadherin promoter. However, mutations within both E-
box elements abolished the repressive effect of δEF1 on
the BMP-6-induced reporter gene activity (Figure 4b, lane
13 verse 15, lane 14 verse 16). These data suggested that
ectopic expression of δEF1 can attenuate BMP-6-induced
transactivation of the E-cadherin promoter through either
the E-box 1 or E-box 3 binding sites in MDA-MB-231 cells.
Mutation of both E-boxes is required to efficiently inter-
fere with the repressive effect of δEF1 on BMP-6-regulated
Ectopic expression of δEF1 is sufficient to attenuate BMP-6-induced transactivation of the E-cadherin in MDA-MB-231 breast  cancer cells Figure 4
Ectopic expression of δEF1 is sufficient to attenuate BMP-6-induced transactivation of the E-cadherin in MDA-
MB-231 breast cancer cells. (a) Western blot with anti-myc antibody was performed to show δEF1-myc expression in 
MDA-MB-231 (∆6B) and MDA-MB-231 (∆δEF1) cells. Actin was used as a loading control. (b) MDA-MB-231 cells on a 6-well 
plate were co-transfected with a δEF1 expression plasmid (2 µg/well) and luciferase E-cadherin promoter constructs (2 µg/
well) following treatment with 200 ng/ml rhBMP-6 after 24 h of transfection. The luciferase activity of the extracts was deter-
mined 24 h after BMP-6 induction using a Betascope analyzer. Luciferase values are normalized with Renilla activities. * indi-
cates p < 0.05 in unpaired student t test when compared with vector alone. Data represent three independent experiments.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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E-cadherin expression. Moreover, the double mutation of
E-boxes not only abolishes the repressive effect of δEF1, it
also blunts the induction effect by BMP-6 on E-cadherin
promoter. Collectively, we can conclude that in MDA-MB-
231 cells, the BMP-6 medicated activation of E-cadherin
gene is closely associated with the ability of E-cadherin
promoter to bind to its putative suppressors (such as
δEF1) through its E-box 1 and E-box 3.
Naturally we were interested in investigating whether
knockdown of δEF1 using RNA interference (RNAi)
would result in an activation of the promoter. To do so, a
small interfering RNA (siRNA) targeting δEF1 or a scram-
bled control siRNA were stably transfected into MDA-MB-
231 cells, followed by treatments with 200 ng/ml rhBMP-
6. The knockdown of δEF1 expression was confirmed by
western blot (Figure 6a), accompanied by a significant
increase in the promoter activity of E-cadherin with or
without BMP-6 treatment, compared to the cells trans-
fected with the control siRNA (Figure 6b). The data veri-
fied that depletion of δEF1 in MDA-MB-231 cells is
sufficient to allow a native expression of the silenced E-
cadherin gene. Furthermore, a knockdown of δEF1 abol-
ished the E-cadherin promoter stimulation by rhBMP-6
(Figure 6b), suggesting that the stimulatory effect of BMP-
6 on E-cadherin transcription occurs indirectly. Down-
regulation of δEF1 is a pre-requisite for BMP-6 to induce
the expression of E-cadherin. While the δEF1 suppression
of the BMP-6-stimulated E-cadherin promoter activity was
dose-dependent, double mutation of E-boxes causes a
total abolishment of the δEF1 effect, given that the mole-
cule was unable to exhibit a repression at any dose when
both E-boxes were mutated (Figure 7).
BMP-6 attenuates the association of endogenous δEF1 
with E-cadherin promoter
As previously demonstrated, we have shown that BMP-6
can down-regulate the repressor, δEF1, to effectively stim-
ulate the E-cadherin promoter. Considering that δEF1 is
directly associated with the E-cadherin proximal promoter
in vivo, acting as a direct transcription repressor [36], we
wished to study this physical interaction in response to
BMP-6 by quantitative CHIP assay. Total protein lysates
from MDA-MB-231 cells treated with or without 200 ng/
ml rhBMP-6 were further incubated with a δEF1 antibody
directed against the δEF1 amino-terminus in order to pre-
cipitate endogenous δEF1. As shown in Figure 8a, δEF1
specifically bound to the -175/+21 region of the E-cad-
herin promoter, and the binding was significantly reduced
by BMP-6 treatment (Figure 8b). This data supports the
notion that BMP-6 stimulation of E-cadherin promoter
takes place through both a reduction of δEF1 expression
and a physical removal of δEF1 from binding to its cog-
nate DNA elements.
Discussion
The progressive and metastatic nature of breast cancer has
been well recognized, yet the mechanisms through which
breast cancer cells acquire their invasive properties have
not been clearly elucidated. Several studies have reported
that breast cancer produces a variety of growth factors that
can play a role in the progression and metastasis of breast
cancer. In the current study, we have uncovered that one
of these factors, BMP-6, contributes to the regulation of E-
cadherin-mediated epithelial-mesenchymal transition of
breast cancer in vitro. In addition, we have shown that the
stimulatory effect of BMP-6 on E-cadherin transcription
occurs through reducing the expression and activity of
δEF1, which we have found to be a strong transcriptional
Scheme of the cloned promoter region of human E-cadherin Figure 5
Scheme of the cloned promoter region of human E-cadherin. The putative δEF1-binding sites (E-box 1 and E-box 3) 
and mutations generated in the δEF1-binding sites are indicated.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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repressor of the E-cadherin gene. Importantly, the reverse
relationship between BMP-6/E-cadherin and δEF1 expres-
sions in cancer cell lines has been verified in clinical
tumor specimens. Our results provide the first evidence, at
the cellular level, to support the hypothesis that breast
cancers may progress and metastasize through the regula-
tion of E-cadherin expression by BMP-6 and δEF1.
Expression of BMPs has been reported to increase with
breast cancer progression. Several studies on the overex-
pression of BMPs, such as BMP-2, BMP-4, and BMP-7 in
mammary tumor cells [45-47] are suggestive of a role of
BMPs in breast cancer development. Clement et al. were
the first to report that BMP-6 is detectable, not only in
breast cancer cell lines, such as MCF-7, SK-BR-3, MDA-
MB-453, BT-20, and ZR-75-1, but also in most tumor
specimens, using RT-PCR and immunohistochemistry
[21]. Importantly, BMP-6 expression was significantly
increased and was most intense in the vicinity of chon-
droid matrix of complex adenomas and mixed benign
tumors of canine mammary glands [1,2]. In agreement
with these reports, we present here our finding that signif-
icantly higher levels of BMP-6 were observed in breast
cancer cell lines and clinical tumor specimens, using
quantitative RT-PCR. Moreover, BMP-6 expression is
higher in the ER+ breast cancer cell line, MCF-7, compared
to the ER- breast cancer cell line, MDA-MB-231. Although
BMP-6 expression levels varied widely among tumor spec-
imens, it was relatively higher in ER+ cases than in ER-
cases. This coincides with our previous finding that BMP-
6 promoter methylation status is correlated with ER status
in breast cancer. In that study, we observed significantly
lower levels of BMP-6 mRNA in ER- breast cancer cells
compared with ER+ breast cancer cells, an effect attributed
to hypermethylation status in the ER- breast cancer cells
[48]. In addition to breast cancer, BMP-6 has been found
in a variety of other cancer cell types, including prostate,
kidney, esophagus, and osteosarcoma [25,49-51], sug-
gesting its association with the progression of tumorigen-
esis.
E-cadherin is ubiquitously expressed by epithelial cells,
from which most cancers are derived. E-cadherin-medi-
ated cell-cell adhesion prevents cells in a primary tumor
from breaking away and invading near or distant sites. It
has been well documented that loss of E-cadherin in
mammary epithelial cells can promote breast cancer pro-
gression and metastasis [52]. Recently, several factors,
including ErbB2 [18], TGF-β [19], and estrogen [20], were
reported to regulate E-cadherin expression through differ-
ent mechanisms. In this study, we have determined that
BMP-6 is a novel stimulus of E-cadherin expression in
breast cancer cells, providing evidence for a potential role
of BMP-6 in tumor progression and metastasis. In addi-
tion, our results indicate that BMP-6-induced expression
of E-cadherin is correlated with ER status. Higher levels of
BMP-6 and E-cadherin transcripts were observed in ER+
breast cancer cells, while lower amounts were detected in
ER- cells. These observations are in line with a previous
finding that loss of E-cadherin expression was associated
with the lack of ER expression and a more aggressive phe-
notype of breast cancer with poor clinical prognosis [20].
Thus, our observations lead us to propose that BMP-6 may
cooperate with other factors, such as estrogen, to partici-
pate in attenuating breast caner progression.
Several epigenetic mechanisms have been implicated in E-
cadherin regulation in breast cancer [53], among these, a
few zinc-finger transcription factors are known to bind to
E-box elements of the E-cadherin promoter and repress
transcription, including Snail1 [11-14], Snail2 [15,16],
Repression of endogenous δEF1 abolishes BMP-6-induced  transactivation of the E-cadherin promoter in MDA-MB-231  breast cancer cells Figure 6
Repression of endogenous δEF1 abolishes BMP-6-
induced transactivation of the E-cadherin promoter 
in MDA-MB-231 breast cancer cells. (a) δEF1-specific 
siRNA plasmid (siRNA-δEF1) was introduced into MDA-MB-
231 cells to generate δEF1-interfered stable transfectants. 
Control cells were treated with a scrambled siRNA. The effi-
ciency of δEF1 protein knockdown was examined by western 
blot, using an anti-ZEB antibody. Actin was used as a loading 
control. (b) δEF1-interfered MDA-MB-231 cell were tran-
siently transfected with luciferase E-caherin promoter con-
structs. After transfection for 24 h, cells were treated with 
200 ng/ml rhBMP-6. The luciferase activity of the extracts 
was determined 24 h after BMP-6 treatment using a Beta-
scope analyzer. Luciferase values are normalized with Renilla 
activities. * indicates p < 0.05 in unpaired student t test when 
compared with vector alone.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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and SIP1 [17]. δEF1, a close homolog of SIP1 [54], was
previously shown to directly bind to E-box elements of the
E-cadherin promoter and inhibit the expression of endog-
enous E-cadherin mRNA and protein in mammary epithe-
lial cells [36]. These previous observations are consistent
with our results demonstrating that overexpression of
δEF1 is sufficient to block transactivation of E-cadherin in
MDA-MB-231 cells. In line with our findings, a recent
paper has also supported a role of δEF1 in E-cadherin
repression in lung cancer cells [38]. In spite of these find-
ings, the upstream factors responsible for regulating the
δEF1/E-cadherin loop in breast cancer have not yet been
identified. Our current work has provided two novel find-
ings in this context, (1) δEF1 can repress BMP-6-mediated
up-regulation of E-cadherin and (2) the integrity of a sin-
gle δEF1-binding element in the proximal E-cadherin pro-
moter is sufficient for the repression effect of δEF1,
providing evidence that BMP-6 may affect E-cadherin-
mediated progression and metastasis through the regula-
tion of specific genes, such as δEF1, during breast tumori-
genesis. Furthermore, the fact that artificial removal of
δEF1 by RNAi enhances gene expression of E-cadherin
supports the important role of δEF1 to be down-regulated
by BMP-6 in the native state in order for BMP-6 to induce
E-cadherin expression. RNAi does it by mediating mRNA
degradation, whereas BMP-6 does it by (1) inhibiting the
expression of δEF1, and (2) by dislodging δEF1 that has
already bound to the E-cadherin gene. Our overall data
demonstrates that δEF1 is a native repressor of E-cadherin
gene. Factors that remove/decrease δEF1 level would sub-
sequently increase the expression of E-cadherin.
Previous research from our group indicated that δEF1
represses BMP-2-induced differentiation of C2C12 myob-
BMP-6-induced transactivation of E-cadherin is suppressed by δEF1 in a dose-dependent manner Figure 7
BMP-6-induced transactivation of E-cadherin is suppressed by δEF1 in a dose-dependent manner. Wild-type or 
mutated human E-cadherin promoter constructs were co-transfected with different amounts of δEF1 expression plasmid (1.5, 
3.0, 6.0 µg/well) into MDA-MB-231 cells, followed by the treatment with 200 ng/ml rhBMP-6 after 24 h of transfection. The 
luciferase activity of the extracts was determined 24 h after BMP-6 treatment using a Betascope analyzer. Luciferase values are 
normalized with Renilla activities. Data represent three independent experiments. * indicates p < 0.05 in unpaired student t 
test when compared with vector alone. ** indicates p < 0.05 in one-way analysis of variance followed by Dunnett's test when 
compared with vector alone.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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lasts into the osteoblast lineage, an effect that is not medi-
ated via the canonical BMP/Smad signaling pathway, but
instead by differential regulation of the AP-1 pathway
[55]. In the study reported here, we found that overexpres-
sion of R-Smads (Smad 1 and 5) failed to augment BMP-
6-induced transactivation of E-cadherin, which is medi-
ated by suppression of δEF1 (data not shown). However,
further studies will be required for a better understanding
of the signal transduction mechanisms regulated by BMP-
6 and δEF1 in breast cancer cells.
Breast cancer metastasis is a complicated process, during
which the important functions of estrogen and the estro-
gen receptor have been consistently recognized [56,57]. In
BMP-6 represses binding of endogenous δEF1 to the E-cadherin proximal promoter in MDA-MB-231 breast cancer cells Figure 8
BMP-6 represses binding of endogenous δEF1 to the E-cadherin proximal promoter in MDA-MB-231 breast 
cancer cells. (a) Association of δEF1 with the E-cadherin promoter region was examined in vivo by CHIP analysis in MDA-MB-
231 cells, using an unrelated anti-FLAG antibody or an anti-ZEB antibody directed against the N-terminal epitopes of δEF1. The 
amplified human E-cadherin promoter fragment is shown (-175/+21). (b) For quantitative CHIP assay, MDA-MB-231 cells were 
treated with or without 200 ng/ml rhBMP-6. Cell lysates were collected after 72 h. The IP was performed using anti-ZEB anti-
body (10 µg) with anti-FLAG antibody (10 µg) as a negative control. DNA fragments containing the E-cadherin promoter 
region (-175/+21) were amplified by quantitative PCR from anti-ZEB and anti-FLAG immunoprecipitated samples. Data repre-
sent three independent experiments. * indicates p < 0.05 in unpaired t-test when compared with un-treated group.BMC Cancer 2007, 7:211 http://www.biomedcentral.com/1471-2407/7/211
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this study, we observed that, in breast cancer cell lines and
clinical tumor specimens, δEF1 was expressed at a higher
level in ER- cells compared to ER+ cells, indicating that
δEF1 might contribute to the malignant conversion of
breast cancer cells towards invasive and metastatic pheno-
types. On the other hand, the contribution of BMP-6 to
tumor metastasis has been recently studied in prostate
cancer, suggesting that BMP-6 plays an important role in
regulating tumor cell invasion [25]. We recently showed
that BMP-6 in ER+ breast cancer cells could be activated by
estrogen through promoter demethylation [29,48]. Con-
sidering our finding that BMP-6-induced E-cadherin
transactivation occurs indirectly, through the reduction of
δEF1 expression, we speculate that overexpression of
BMP-6 by breast cancer cells may represent a novel mech-
anism that regulates specific target genes such as E-cad-
herin and δEF1, in modulating metastasis and invasion of
breast cancer.
Conclusion
Our data suggest that the stimulatory effect of BMP-6 on
E-cadherin transcription in breast cancer cells occurs indi-
rectly, through the reduced expression and activity of
δEF1. Repressors of BMP-6 and E-cadherin, such as δEF1,
may regulate breast tumor progression and metastasis at
different stages, including the initial de-differentiation of
primary tumor cells and the maintenance of migratory
and/or undifferentiated phenotypes. Further studies
should be focused on better understanding of the signal
transduction mechanisms and the relationship between
BMP-6 and δEF1 in breast cancer formation, progression,
and metastasis.
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